The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1265
July 16, 2007
View Complete Issue         Table of Contents 2019 
Thiazolidinediones and Cardiovascular Disease
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Thiazolidinediones and Cardiovascular Disease
July 16, 2007 (Issue: 1265)
The thiazolidinediones rosiglitazone (Avandia) and pioglitazone (Actos) are peripheral insulin sensitizing agents used to treat hyperglycemia in patients with type 2 diabetes; one or the other is often used as a second or third agent with metformin...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Thiazolidinediones and Cardiovascular Disease
Article code: 1265a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.